Celldex to Showcase Mast Cell Targeting Pipeline at EAACI Congress
Event summary
- Celldex will present three data sets at the 2026 EAACI Congress in Istanbul, June 12-15.
- Two flash talks will focus on barzolvolimab's clinical profile in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU).
- A late-breaking poster will reveal first-in-human Phase 1 results for CDX-622, a bispecific antibody targeting TSLP and mast cells.
- Barzolvolimab is in Phase 3 trials for CSU and ColdU/SD, with additional indications planned.
The big picture
Celldex's presentations at EAACI highlight its focus on mast cell-targeting therapies, a niche with growing interest in treating allergic and inflammatory disorders. The company is positioning barzolvolimab as a potential best-in-disease treatment, while CDX-622 represents a novel approach to dual-pathway inhibition. Success in these programs could solidify Celldex's leadership in immunology, but competition and regulatory hurdles remain significant.
What we're watching
- Clinical Validation
- Whether barzolvolimab's first-in-class status in CSU and ColdU can be sustained through Phase 3 trial results.
- Pipeline Diversification
- The pace at which CDX-622 advances through early-stage trials and expands into inflammatory and fibrotic disorders.
- Regulatory Pathways
- How Celldex navigates the regulatory landscape for novel mast cell-targeting therapies.
Related topics